A Phase 1 interventional study of Placebo control and NRL001 cream in Fecal Incontinence, sponsored by Norgine. Completed at 1 site in Bulgaria. Open to participants aged 21 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-08-01.
Sponsored by Norgine · Phase 1, Interventional, and Treatment
This study is conducted to explore the safety and tolerability and plasma pharmacokinetics of NRL001 after single intra-anal dose of 1mL cream at increasing concentrations.
312 studies on the registry are indexed under Fecal Incontinence; 57 are open to participants now.
This study's enrollment of 12 is below the median of 50 across 216 interventional studies indexed under Fecal Incontinence.
Browse Fecal Incontinence studies →Norgine is the lead sponsor of 52 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
IN.1) sex: male and female (non-child-bearing potential or using medically adequate contraception
IN.2) race: Caucasian
IN.3) BW: 50 - 100 kg
IN.4) BMI: 20 - 28 kg.m-2
IN.5) age: 21 - 50 years
IN.6) type: healthy on the basis of specified criteria evaluated at the screening visit
IN.7) willing and able to provide informed consent
Exclusion Criteria:
General
EX.1) Previous participation in the trial
EX.2) Participant in any other trial during the last 90 days
EX.3) Donation of blood during the last 60 days or a history of blood loss exceeding 300 mL within the last 3 months
EX.4) History of any clinically relevant allergy (including hypersensitivity to the trial medications)
EX.5) Presence of acute or chronic infection
EX.6) Presence or history of any relevant co-morbidity
EX.7) Resting systolic blood pressure > 140 or \< 90 mmHg, diastolic blood pressure > 95 or \< 50 mmHg
EX.8) Clinically relevant ECG-abnormalities, prolonged QTc with > 450 msec in males and > 460 msec in females in particular
EX.9) Presence of any relevant abnormality in the laboratory safety tests, especially low haemoglobin, increased liver enzymes
EX.10) Positive serology for HBsAg, anti HBc and anti HCV
EX.11) Positive HIV test
EX.12) Positive alcohol or urine drug test on recruitment (and upon admission)
EX.13) History of alcohol and/or drug abuse and/or daily use of > 30 gr alcohol
EX.14) Smoking more than 15 cigarettes/day or equivalent of other tobacco products
EX.15) Use of prohibited medication
EX.16) Suspicion or evidence that the subject is not trustworthy and reliable
EX.17) Suspicion or evidence that the subject is not able to make a free consent or to understand the information in this regard
General - all females
EX.18) Positive pregnancy test
EX.19) Lactating
EX.20) Not using appropriate contraception in pre-menopausal women (note: under the conditions of the present study, women using hormonal contraceptives will be informed that this method is not sufficient during the study and that further i.e. mechanical methods [condom, diaphragm with spermicidal gel] should be used in addition).
Placebo control
Drug: Placebo control
0.5% NRL001 cream
Drug: NRL001 cream
0.75% NRL001 cream
Drug: NRL001 cream
1.0% NRL001 cream
Drug: NRL001 cream
Placebo cream
Cream for single-dose intra-anal application
Cmax of NRL001
Time frame: 30 mins, 1, 2, 3, 4, 5, 6, 8 and 12 hours after dosing
AUC of NRL001
Time frame: 30 mins, 1, 2, 3, 4, 5, 6, 8 and 12 hours after dosing
Tolerability of NRL001
Spontaneously reported adverse events will be recorded
Time frame: Up to 12 hours post-dosing
This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Norgine